Research programme: skeletal muscle activators - Cytokinetics/Astellas

Drug Profile

Research programme: skeletal muscle activators - Cytokinetics/Astellas

Alternative Names: CK 3672889; CK-1909178; CK-2066260

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Cytokinetics
  • Developer Astellas Pharma; Cytokinetics
  • Class Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Muscular atrophy

Most Recent Events

  • 27 Jul 2016 Cytokinetics and Astellas Pharma expand their collaboration for discovery of skeletal muscle activators through 2017 and also include Amyotrophic lateral sclerosis in target indications
  • 30 Jul 2015 Preclinical development is ongoing in USA
  • 01 May 2014 No development reported - Preclinical for Muscular atrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top